Hansa Biopharma — December 2025
-
Godmorgen
ja det går sku ikke særligt godt heller ikke med den nye top chef hold nu op hvor er det her gået hen og blevet en møj case ( har den desværre i 4 depoter og alt for mange) de brænder simpelthen for mange penge af uden at få omsætning op i gear og så ved alle jo hvordan det ender -
Hansa Biopharma: Negative anti-GBM Phase III Readout
.. "The relative valuation of anti-GBS was comparatively modest in our base case at around SEK8 per share. We therefore view this negative outcome as a moderate setback, given the significantly larger kidney indication." ..
-
-
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind